Alpha TeknovaTKNO
About: Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.
Employees: 211
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.56% less ownership
Funds ownership: 14.91% [Q1] → 14.35% (-0.56%) [Q2]
10% less funds holding
Funds holding: 31 [Q1] → 28 (-3) [Q2]
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
49% less capital invested
Capital invested by funds: $15.8M [Q1] → $8.03M (-$7.79M) [Q2]
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for TKNO.